Curis, Inc.
Key Metrics
Market Snapshot
About
Curis, Inc. is a biotechnology company focused on developing innovative therapeutics for the treatment of cancer. Headquartered in Lexington, Massachusetts, the company's pipeline includes targeted small molecule and immuno-oncology drug candidates. Curis's lead programs include emavusertib, a selective oral IRAK4 inhibitor for hematologic and solid tumors, and CA-4948, an IRAK4 inhibitor being evaluated in collaboration with Aurigene Discovery Technologies. The company has strategic partnerships with major pharmaceutical companies and focuses on precision medicine approaches to cancer treatment.